Probiotic preparation VSL#3 for induction of remission in ulcerative colitis: a systematic review

Chinese Journal of Gastroenterology

Volumn 17, Issue 9, 2012, Pages 521-526

  Ding, Juan ^a   Xiong, Guangsu ^a   Yang, Chuanhua ^a   Wu, Jianghong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Colitis, ulcerative; Meta analysis; Probiotics; Remission induction; VSL 3

Indexed keywords

PROBIOTIC AGENT;

ARTICLE; CONTROLLED STUDY; DRUG SAFETY; DRUG SYNTHESIS; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

EID: 84871244612     PISSN: 10087125     EISSN: None     Source Type: Journal    
DOI: 10.3969/j.issn.1008-7125.2012.09.002     Document Type: Article

References (18)

1. Inaba Y, Ashida T, Ito T, et al. Expression of the antimicrobial peptide alpha-defensin/cryptdins in intestinal crypts decreases at the initial phase of intestinal inflammation in a model of inflammatory bowel disease, IL-10-deficient mice[J]. Inflamm Bowel Dis, 2010, 16 (9): 1488-1495.
2. Hammer H F. Gut microbiota and inflammatory bowel disease[J]. Dig Dis, 2011, 29 (6): 550-553.
3. 2008, 17 (2): 114-118.
4. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease[J]. Dig Dis Sci, 2008, 53 (9): 2524-2531.
5. Sang L X, Chang B, Zhang W L, et al. Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis[J]. World J Gastroenterol, 2010, 16 (15): 1908-1915.
6. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis[J]. Am J Gastroenterol, 2009, 104 (2): 437-443.
7. Sood A, Midha V, Makharia G K, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis[J]. Clin Gastroenterol Hepatol, 2009, 7 (11): 1202-1209, 1209.e1.
8. Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis[J]. Aliment Pharmacol Ther, 2012, 35 (3): 327-334.
9. Matthes H, Krummenerl T, Giensch M, et al. Clinical trial: probiotic treatment of acute distal ulcerative colitis with rectally administered Escherichia coli Nissle 1917 (EcN)[J]. BMC Complement Altern Med, 2010, 10: 13.
10. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study[J]. Am J Gastroenterol, 2010, 105 (10): 2218-2227.
11. Furrie E, Macfarlane S, Kennedy A, et al. Synbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomised controlled pilot trial[J]. Gut, 2005, 54 (2): 242-249.
12. Kato K, Mizuno S, Umesaki Y, et al. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis[J]. Aliment Pharmacol Ther, 2004, 20 (10): 1133-1141.
13. Tursi A, Brandimarte G, Giorgetti G M, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis[J]. Med Sci Monit, 2004, 10 (11): PI126-PI131.
14. Rembacken B J, Snelling A M, Hawkey P M, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial[J]. Lancet, 1999, 354 (9179): 635-639.
15. 2007, 12 (8): 488-495.
16. Chapman T M, Plosker G L, Figgitt D P. VSL#3 probiotic mixture: a review of its use in chronic inflammatory bowel diseases[J]. Drugs, 2006, 66 (10): 1371-1387.
17. Gionchetti P, Lammers K M, Rizzello F, et al. VSL#3: an analysis of basic and clinical contributions in probiotic therapeutics[J]. Gastroenterol Clin North Am, 2005, 34 (3): 499-513, ix-x.
18. Pronio A, Montesani C, Butteroni C, et al. Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells[J]. Inflamm Bowel Dis, 2008, 14 (5): 662-668.